A new era in the treatment of urothelial carcinoma

Urol Oncol. 2023 Oct 11:S1078-1439(23)00294-6. doi: 10.1016/j.urolonc.2023.08.020. Online ahead of print.ABSTRACTThe advances in targeted therapies, immunotherapy, and the recent emergence of antibody-drug conjugates (ADCs) herald a potential paradigm shift in treating patients with metastatic urothelial cancer. Yet, there are inherent challenges in utilizing these therapies, including the management of treatment-related toxicities. In this special Urologic Oncology: Seminars and Original Investigations issue, we review the latest developments and discuss insights into future research needs.PMID:37833099 | DOI:10.1016/j.urolonc.2023.08.020
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Source Type: research